The Science of Monoclonal Antibodies: How Burosumab Blocks FGF23 to Restore Phosphate

Tumor-induced osteomalacia (TIO) is a rare disorder in which certain tumors produce excess fibroblast growth factor 23 (FGF23). Elevated FGF23 lowers blood phosphate, leading to weak bones, muscle pain, and fatigue. Burosumab (brand name Crysvita) is a monoclonal antibody designed to bind and neutralize FGF23, restoring normal phosphate levels. Here’s how it works, why it matters, and what patients and caregivers should know.

Why Phosphate Matters

Phosphate is essential for:

• Bone mineralization and strength
• Muscle contraction
• Energy production (ATP synthesis)
• Cellular signaling and DNA function

Low phosphate (hypophosphatemia) can cause:

• Bone pain, fractures, and deformities
• Muscle weakness and cramps
• Fatigue and reduced quality of life

In TIO, tumors secrete FGF23, which:

• Reduces phosphate reabsorption in the kidneys
• Inhibits activation of vitamin D (1,25-dihydroxyvitamin D)
• Leads to chronic phosphate loss

Burosumab Crysvita for Tumor-Induced Osteomalacia

Burosumab is a fully human monoclonal antibody that specifically targets and blocks FGF23. Approved under the brand name Crysvita, it was first authorized for X-linked hypophosphatemia (XLH) and, more recently, for TIO when the causative tumor can’t be located or removed.

Key points:

• Molecular weight: ~150 kDa
• Route: Subcutaneous injection
• Dosing: Every 2–4 weeks, tailored to serum phosphate levels
• Goal: Raise and maintain serum phosphate in the low-normal range

Mechanism of Action

1. Binding to FGF23
   Burosumab binds circulating FGF23 with high affinity, preventing it from interacting with its receptor complex (FGFR1 and co-receptor Klotho) in kidney cells.
2. Restoring Phosphate Reabsorption
   With FGF23 blocked, sodium-phosphate co-transporters (NaPi-IIa/IIc) in the kidney’s proximal tubules increase phosphate reabsorption.
3. Enhancing Vitamin D Activation
   Burosumab allows 1α-hydroxylase to convert 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D, boosting intestinal phosphate and calcium absorption.
4. Improving Bone Mineralization
   Higher serum phosphate and active vitamin D levels facilitate normal bone mineralization, reducing pain and fracture risk.

Clinical Evidence

Several studies support Burosumab’s use in TIO:

• Phase 2 Open-Label Study (J Clin Endocrinol Metab, 2020)
  • 14 adult patients with unresectable TIO
  • Burosumab dosed every 4 weeks for 144 weeks
  • Result: Significant increase in serum phosphate; 71% achieved normalization by week 24
  • Improvements in bone pain, fracture healing, and physical function

• Long-Term Follow-Up
  • Sustained phosphate correction up to 3 years
  • Continued improvements in patient-reported outcomes (fatigue, pain)
  • Well tolerated, with no new safety signals

Administration and Monitoring

Burosumab requires careful dosing and monitoring:

1. Baseline Assessment
   • Serum phosphate, calcium, vitamin D, FGF23
   • Kidney function and urine calcium
2. Dosing Schedule
   • Initial dose: 0.3–0.6 mg/kg every 4 weeks
   • Adjust based on trough serum phosphate (target: 2.5–4.5 mg/dL)
3. Monitoring
   • Serum phosphate before each dose
   • Calcium and parathyroid hormone (PTH) every 3 months
   • Renal ultrasound annually (monitor for nephrocalcinosis)
4. Duration of Therapy
   • Long-term treatment may be required if tumor cannot be removed
   • Periodic reevaluation for tumor localization is recommended

Benefits and Potential Risks

Understanding benefits and risks helps set realistic expectations.

Benefits:

• Rapid and sustained increase in serum phosphate
• Improved bone pain, muscle strength, and fracture healing
• Enhanced quality of life and physical function

Potential Risks:

• Injection-site reactions (pain, redness, swelling)
• Hypersensitivity reactions (rare)
• Elevated calcium or urine calcium—monitor for kidney calcifications
• Potential for overcorrection—requires dose adjustment

Who May Benefit?

• Patients diagnosed with TIO in whom the tumor cannot be located or fully resected
• Individuals experiencing persistent hypophosphatemia despite conventional therapy (oral phosphate and active vitamin D supplements)
• Those seeking an alternative to frequent dosing of oral phosphate, which can cause gastrointestinal side effects

Practical Considerations

• Burosumab is typically administered at specialized centers or by trained healthcare providers.
• Insurance coverage may vary; patient assistance programs exist.
• Coordination with endocrinologists, nephrologists, and oncologists ensures comprehensive care.

Everyday Tips for Managing TIO with Burosumab

• Keep a dosing and lab-monitoring calendar to track appointments and results.
• Report any new symptoms (e.g., worsening bone pain, muscle cramps) to your care team promptly.
• Maintain a balanced diet rich in natural sources of phosphate (e.g., dairy, nuts, legumes) unless otherwise directed.
• Stay active within comfort limits to support bone strength—physical therapy may be helpful.

When to Seek Medical Advice

If you experience any of the following, speak to a doctor right away:

• Severe bone pain or sudden fractures
• Signs of severe allergic reaction (hives, difficulty breathing)
• Unexplained swelling or weight changes
• Persistent gastrointestinal upset or dehydration

For non-urgent concerns or initial symptom exploration, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Call or visit your healthcare provider if you suspect anything could be serious or life-threatening. Always discuss treatment options, potential side effects, and laboratory monitoring with your doctor before starting Burosumab Crysvita for tumor-induced osteomalacia.

---

Disclaimer: This information is for educational purposes and is not a substitute for professional medical advice. Always consult a qualified healthcare provider for personalized guidance.